Pharmacokinetics of Testosterone Lotion in the Treatment of Hypogonadal Males

Acrux DDS

Status and phase: Completed; Phase 2

Conditions: Hypogonadism

Treatments: Drug: Testosterone

Study type: Interventional

Funder types: Industry

Identifiers

NCT00372008

MTE05

Details and patient eligibility

About

Testosterone replacement treatment is the most effective way of treating hypogonadism in men. Acrux has a proprietry testosterone replacement product - Testosterone-MD Lotion, and this study will evaluate the efficacy and safety of this product.

Enrollment: 40 estimated patients

Sex: Male

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Hypogonadal males between 18-70 years old with qualifying general medical health

Exclusion criteria

• Disqualifying concurrent conditions or allergy/sensitivity to testosterone replacement therapy